E-mail

E-mail a Wiley Online Library Link

Hanna Jean Khoury, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Maria Cielo Foudray, Martha Arellano, Amelia Langston, Beverly Bethelmie-Bryan, Selena Rush, Kevin Litwiler, Sharon Karan, Heidi Simmons, Adam I. Marcus, Mieke Ptaszynski and Hagop Kantarjian A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias Cancer 118

Version of Record online: 2 DEC 2011 | DOI: 10.1002/cncr.26664

This report discusses a phase 1 trial that identified the maximum tolerated dose and describes the adverse events associated with ARRY-520. The pharmacokinetics of ARRY-520 are reported, as are images of the appearance of abnormal monopolar spindle formation and apoptosis following administration of ARRY-520.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH